Mayne Pharma Group Stock Analysis

Mayne Pink Sheet Analysis Notes

About 23.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mayne Pharma Group recorded a loss per share of 0.03. The entity last dividend was issued on the 18th of January 2023. The firm had 987:937 split on the 30th of June 2016. Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. Mayne Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange.The quote for Mayne Pharma Group is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Mayne Pharma Group contact Shawn BSc at 61 8 8209 2666 or learn more at https://www.maynepharma.com.

Mayne Pharma Group Investment Alerts

Mayne Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 235.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mayne Pharma's market, we take the total number of its shares issued and multiply it by Mayne Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Mayne Profitablity

The company has Profit Margin (PM) of (0.62) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.17) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.17.

Technical Drivers

As of the 12th of December 2024, Mayne Pharma secures the Mean Deviation of 1.47, risk adjusted performance of 0.0524, and Standard Deviation of 4.18. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mayne Pharma Group, as well as the relationship between them. Please verify Mayne Pharma Group standard deviation, as well as the relationship between the maximum drawdown and kurtosis to decide if Mayne Pharma Group is priced some-what accurately, providing market reflects its recent price of 3.1 per share. Given that Mayne Pharma Group has information ratio of 0.034, we recommend you to check Mayne Pharma's last-minute market performance to make sure the company can sustain itself at a future point.

Mayne Pharma Group Price Movement Analysis

Mayne Pharma Predictive Daily Indicators

Mayne Pharma Forecast Models

Mayne Pharma's time-series forecasting models are one of many Mayne Pharma's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mayne Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Mayne Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mayne shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Mayne Pharma. By using and applying Mayne Pink Sheet analysis, traders can create a robust methodology for identifying Mayne entry and exit points for their positions.

When running Mayne Pharma's price analysis, check to measure Mayne Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mayne Pharma is operating at the current time. Most of Mayne Pharma's value examination focuses on studying past and present price action to predict the probability of Mayne Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mayne Pharma's price. Additionally, you may evaluate how the addition of Mayne Pharma to your portfolios can decrease your overall portfolio volatility.